Non-steroidal anti-inflammatory drugs (NSAIDs) are the competitive inhibitors of
cyclooxygenase (COX), the enzyme which mediates the bioconversion of arachidonic acid …

Along with the development of marine biological pharmaceutical research, high‐effective
and low‐toxic drugs and functional foods isolated from marine organisms have become a …

This review focuses on new findings and controversial issues in the pathology and
molecular biology of adenocarcinoma of the prostate. Since management of high-grade …

By optimizing binding to a selected target protein, modern drug research strives to develop
safe and efficacious agents for the treatment of disease. Selective drug action is intended to …

Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing
cancer. One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the …

Several lines of evidence suggest that cyclooxygenase-2 (COX-2) is a rational target for
anticancer therapy. Epidemiological studies have shown that use of nonsteroidal anti …

Abstract Cyclooxygenase–2 (COX–2)–controlled prostaglandin (PG) metabolism recently
has been implicated in the pathogenesis of hepatocellular carcinoma (HCC). However, the …

Celecoxib is a paradigmatic selective inhibitor of cyclooxygenase-2 (COX-2). This anti-
inflammatory drug has potent anti-tumor activity in a wide variety of human epithelial tumor …

The results of cisplatin-based chemotherapy seem to have reached a plateau, and empirical
approaches are targeting the inclusion of novel biological agents with different mechanisms …

Colorectal cancer is the second leading cause of mortality in the United States. In the United
States, the cumulative lifetime risk of developing colorectal cancer for both men and women …